アデノ随伴ウイルス（AAV）受託開発・製造機関の世界市場

アデノ随伴ウイルス（AAV）受託開発・製造機関の世界市場は2030年までに19億米ドルに達する見込み

2024年に7億5,550万米ドルと推定されるアデノ随伴ウイルス（AAV）受託開発・製造機関の世界市場は、2024年から2030年にかけてCAGR 16.5％で成長し、2030年には19億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるダウンストリーム処理ワークフローは、CAGR 19.4％を記録し、分析期間終了までに12億米ドルに達すると予測されます。上流処理ワークフロー分野の成長率は、分析期間でCAGR 12.3％と推定されます。

米国市場は推定2億580万米ドル、中国はCAGR22.3％で成長予測

米国のアデノ随伴ウイルス（AAV）受託開発・製造機関市場は、2024年に2億580万米ドルと推定されます。世界第2位の経済大国である中国は、2024年から2030年の分析期間においてCAGR 22.3%で推移し、2030年には4億2,430万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ11.8%と15.0%と予測されています。欧州では、ドイツがCAGR約13.2%で成長すると予測されています。

世界のアデノ随伴ウイルス（AAV）受託開発・製造機関市場- 主要動向と促進要因のまとめ

なぜAAVベースの遺伝子治療がCDMOサービスの需要を牽引しているのか？

AAVベースの遺伝子治療の採用が増加していることが、ウイルスベクター生産に特化した開発製造受託機関（CDMO）の成長を促進する主な要因となっています。AAVは、その安全性プロファイル、長期的な遺伝子発現能力、希少遺伝性疾患、腫瘍学、神経変性疾患など幅広い治療領域への適用可能性から、遺伝子治療に選択されるベクターとして台頭してきました。遺伝子治療候補の世界のパイプラインが拡大し続ける中、バイオ医薬品企業は、専門知識を活用し、市場投入までの時間を短縮し、規制遵守を確保するため、AAVの開発と製造を専門のCDMOに委託するケースが増えています。さらに、AAVベクターを利用する臨床試験の増加により、厳格な品質基準を満たすスケーラブルで効率的な製造プロセスに対するCDMOへの依存度が高まっていることが浮き彫りになっています。上流および下流処理の課題を含むAAV製造の複雑さは、専門的な知識とインフラを必要とするため、バイオテクノロジー企業はCDMOと連携して製造を合理化し、中核的な研究と商業化の取り組みに集中するようになっています。

技術革新はどのようにAAV製造能力を高めているのか？

バイオプロセス技術と製造プラットフォームにおける急速な進歩は、AAV製造に革命をもたらし、CDMOがより効率的でスケーラブル、かつコスト効率の高いソリューションを顧客に提供することを可能にしています。懸濁細胞培養システム、高収率精製技術、自動化主導型バイオ製造などの革新により、CDMOはAAV製造における従来のボトルネックを克服しつつあります。シングルユース・バイオリアクターやクローズドシステム製造の採用は、柔軟性をさらに高め、汚染リスクを低減し、CDMOが商業規模の生産に対する需要の高まりに対応しやすくしています。さらに、バイオプロセスの最適化における人工知能（AI）と機械学習の統合は、収量の予測可能性と業務効率を向上させています。AAVベースの遺伝子治療が商業化に向けて前進する中、CDMOは製品の一貫性と規制コンプライアンスを維持しながら大量生産をサポートする次世代製造技術に多額の投資を行っています。このような技術の進歩により、生産コストと納期が短縮され、バイオ医薬品企業は遺伝子治療をより迅速かつ競争力のある価格で市場に投入できるようになっています。

AAV CDMOセクターにはどのような規制上の課題と市場機会が存在するか？

AAVベースの遺伝子治療の規制状況は急速に進化しており、この領域で事業を展開するCDMOに課題と機会の両方を生み出しています。米国FDA、欧州医薬品庁（EMA）、その他の世界の規制機関によって課される厳しい規制要件は、厳格な品質管理、プロセスバリデーション、適正製造規範（GMP）の遵守を義務付けています。これらの要件を満たすことはバイオ医薬品企業にとって大きな課題であり、規制遵守を深く理解した専門CDMOへの需要が高まっています。その一方で、規制当局は早期承認や希少疾病用医薬品の指定を通じて遺伝子治療薬の開発を積極的に支援しており、CDMOがサービスを拡大する新たな機会を創出しています。バイオ製造における透明性とトレーサビリティの重視の高まりは、CDMOに電子バッチ記録やリアルタイムモニタリングシステムなどのデジタルソリューションの導入を促し、コンプライアンス基準を満たし、業務効率を向上させています。さらに、地政学的な不確実性や物流の課題に照らして、世界のサプライチェーンの弾力性に対するニーズが高まっていることから、バイオ製薬企業は、マルチサイト製造能力と地理的多様性を備えたCDMOを求めるようになっています。

AAV CDMO市場の成長を促す主な要因とは？

AAV受託開発・製造機関市場の成長は、遺伝子治療の承認件数の増加、商業規模のAAV生産に対する需要の高まり、バイオ医薬品企業のアウトソーシング傾向の高まりなど、いくつかの要因によって牽引されています。眼科、血液内科、循環器内科などの新興治療領域におけるAAVベクターの応用拡大が市場成長をさらに後押ししており、企業は臨床および商業供給のニーズをサポートする信頼できる製造パートナーを求めています。さらに、個別化医療や標的遺伝子導入ソリューションが重視されるようになったことで、ニッチな患者集団に対応できる柔軟でスケーラブルな製造プラットフォームに対する需要が高まっています。バイオテクノロジー研究への投資増加や、ベンチャーキャピタルや政府機関からの資金流入も、バイオテクノロジー新興企業が多額の資本支出なしにCDMOサービスを活用できるようにすることで、市場拡大に寄与しています。さらに、AAV CDMO市場内の競合情勢は、AAVベースの遺伝子治療に対する世界の需要の高まりに対応するため、各社がその能力と地域的リーチを強化しようとしているため、戦略的提携、合併、買収が見られます。

セグメント

ワークフロータイプ（下流処理ワークフロー、上流処理ワークフロー）、培養タイプ（接着培養、懸濁培養）、用途（細胞・遺伝子治療開発用途、ワクチン開発用途、バイオ医薬品・創薬用途、バイオメディカル研究用途）、最終用途（製薬・医薬品企業最終用途、学術・研究機関最終用途）

調査対象企業の例

• Aldevron LLC
• Biovian Oy
• Catalent, Inc.
• Charles River Laboratories International, Inc.
• Creative Biogene
• Esco Aster Pte. Ltd.
• Genezen, Inc.
• Oxford Biomedica PLC
• Porton Advanced
• ProBio Inc.
• Takara Bio, Inc.
• Thermo Fisher Scientific, Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market to Reach US$1.9 Billion by 2030

The global market for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations estimated at US$755.5 Million in the year 2024, is expected to reach US$1.9 Billion by 2030, growing at a CAGR of 16.5% over the analysis period 2024-2030. Downstream Processing Workflow, one of the segments analyzed in the report, is expected to record a 19.4% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Upstream Processing Workflow segment is estimated at 12.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$205.8 Million While China is Forecast to Grow at 22.3% CAGR

The Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations market in the U.S. is estimated at US$205.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$424.3 Million by the year 2030 trailing a CAGR of 22.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.8% and 15.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.2% CAGR.

Global Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market - Key Trends & Drivers Summarized

Why Are AAV-Based Gene Therapies Driving Demand for CDMO Services?

The rising adoption of AAV-based gene therapies is a major driver fueling the growth of contract development and manufacturing organizations (CDMOs) specializing in viral vector production. AAV has emerged as the vector of choice for gene therapy due to its safety profile, long-term gene expression capabilities, and broad applicability across a wide range of therapeutic areas, including rare genetic disorders, oncology, and neurodegenerative diseases. As the global pipeline of gene therapy candidates continues to expand, biopharmaceutical companies are increasingly outsourcing AAV development and manufacturing to specialized CDMOs to leverage their expertise, reduce time-to-market, and ensure regulatory compliance. Furthermore, the increasing number of clinical trials utilizing AAV vectors underscores the growing reliance on CDMOs for scalable and efficient production processes that meet stringent quality standards. The complexity of AAV manufacturing, including upstream and downstream processing challenges, necessitates specialized knowledge and infrastructure, prompting biotechnology firms to collaborate with CDMOs to streamline production and focus on core research and commercialization efforts.

How Is Technological Innovation Enhancing AAV Manufacturing Capabilities?

Rapid advancements in bioprocessing technologies and manufacturing platforms are revolutionizing AAV production, allowing CDMOs to offer more efficient, scalable, and cost-effective solutions to their clients. Innovations such as suspension cell culture systems, high-yield purification techniques, and automation-driven biomanufacturing are enabling CDMOs to overcome traditional bottlenecks in AAV production. The adoption of single-use bioreactors and closed-system manufacturing is further enhancing flexibility and reducing contamination risks, making it easier for CDMOs to meet the growing demand for commercial-scale production. Additionally, the integration of artificial intelligence (AI) and machine learning in bioprocess optimization is improving yield predictability and operational efficiency. As AAV-based gene therapies advance toward commercialization, CDMOs are investing heavily in next-generation manufacturing technologies to support high-volume production while maintaining product consistency and regulatory compliance. These technological advancements are helping reduce production costs and turnaround times, enabling biopharmaceutical companies to bring gene therapies to market more rapidly and at competitive pricing.

What Regulatory Challenges and Market Opportunities Exist in the AAV CDMO Sector?

The regulatory landscape for AAV-based gene therapies is evolving rapidly, creating both challenges and opportunities for CDMOs operating in this space. Stringent regulatory requirements imposed by agencies such as the U.S. FDA, European Medicines Agency (EMA), and other global regulatory bodies mandate rigorous quality control, process validation, and compliance with Good Manufacturing Practices (GMP). Meeting these requirements presents a significant challenge for biopharma companies, driving the demand for specialized CDMOs with a deep understanding of regulatory compliance. On the other hand, regulatory agencies are actively supporting the development of gene therapies through accelerated approval pathways and orphan drug designations, creating new opportunities for CDMOs to expand their service offerings. The increasing emphasis on transparency and traceability in biomanufacturing is prompting CDMOs to implement digital solutions, such as electronic batch records and real-time monitoring systems, to meet compliance standards and improve operational efficiency. Additionally, the rising need for global supply chain resilience in light of geopolitical uncertainties and logistical challenges is encouraging biopharma companies to seek CDMOs with multi-site manufacturing capabilities and geographic diversification.

What Are the Key Factors Driving Growth in the AAV CDMO Market?

The growth in the AAV Contract Development and Manufacturing Organizations market is driven by several factors, including the increasing number of gene therapy approvals, rising demand for commercial-scale AAV production, and the growing trend of outsourcing among biopharmaceutical companies. The expanding application of AAV vectors in emerging therapeutic areas such as ophthalmology, hematology, and cardiology is further propelling market growth, as companies seek reliable manufacturing partners to support clinical and commercial supply needs. Moreover, the growing emphasis on personalized medicine and targeted gene delivery solutions is driving the demand for flexible and scalable manufacturing platforms that can cater to niche patient populations. The rising investment in biotechnology research and the influx of funding from venture capital firms and government agencies are also contributing to market expansion by enabling biotech startups to leverage CDMO services without significant capital expenditures. Furthermore, the competitive landscape within the AAV CDMO market is witnessing strategic partnerships, mergers, and acquisitions, as companies seek to strengthen their capabilities and geographic reach to better serve the growing global demand for AAV-based gene therapies.

SCOPE OF STUDY:

The report analyzes the Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Workflow Type (Downstream Processing Workflow, Upstream Processing Workflow); Culture Type (Adherent Culture, Suspension Culture); Application (Cell and Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical and Pharmaceutical Discovery Application, Biomedical Research Application); End-Use (Pharmaceutical and Biopharmaceutical Companies End-Use, Academic and Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Aldevron LLC
• Biovian Oy
• Catalent, Inc.
• Charles River Laboratories International, Inc.
• Creative Biogene
• Esco Aster Pte. Ltd.
• Genezen, Inc.
• Oxford Biomedica PLC
• Porton Advanced
• ProBio Inc.
• Takara Bio, Inc.
• Thermo Fisher Scientific, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Demand for Gene Therapies Propels the Growth of AAV CDMOs as Key Enablers of Biopharmaceutical Innovation
  • Expanding Pipeline of Rare Disease Treatments Strengthens the Business Case for AAV Manufacturing Services
  • Increasing FDA Approvals for Gene Therapy Products Drive the Need for Scalable AAV Production Capabilities
  • Technological Advancements in AAV Vector Engineering Enhance Efficiency and Productivity in CDMO Operations
  • Growing Strategic Collaborations Between Biotech Companies and CDMOs Accelerate Market Expansion
  • Rising Outsourcing Trends in Biopharma Strengthen Demand for AAV CDMOs to Reduce Time-to-Market
  • Shift Towards Personalized Medicine Fuels Demand for Flexible and Scalable AAV Manufacturing Solutions
  • Growing Investments in Cell and Gene Therapy Research Drive the Expansion of AAV Manufacturing Capabilities
  • Increasing Demand for High-Purity and High-Titer AAV Vectors Spurs Innovation in Manufacturing Processes
  • Global Expansion of Biopharmaceutical Facilities Strengthens the Market Position of AAV CDMOs
  • The Evolution of Viral Vector Platforms Encourages the Adoption of Next-Generation AAV Technologies
  • Growing Number of Clinical Trials Utilizing AAV Vectors Expands the Market Potential for CDMO Services
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Downstream Processing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Downstream Processing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Downstream Processing Workflow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Upstream Processing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Upstream Processing Workflow by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Upstream Processing Workflow by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Pharmaceutical & Biopharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Pharmaceutical & Biopharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Adherent Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Adherent Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Adherent Culture by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Suspension Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Suspension Culture by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Suspension Culture by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Cell & Gene Therapy Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Cell & Gene Therapy Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Cell & Gene Therapy Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Vaccine Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Vaccine Development Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Vaccine Development Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Biopharmaceutical & Pharmaceutical Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Biopharmaceutical & Pharmaceutical Discovery Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Biopharmaceutical & Pharmaceutical Discovery Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Biomedical Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Biomedical Research Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Biomedical Research Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 35: USA Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• JAPAN
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 59: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Japan Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: Japan 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• CHINA
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 71: China Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: China Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: China 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 74: China Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• EUROPE
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 83: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 84: Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• FRANCE
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• GERMANY
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 134: UK Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: UK Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: UK 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 137: UK Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 140: UK Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 146: Spain Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Spain Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Spain 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 149: Spain Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Spain Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Spain 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 158: Russia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Russia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Russia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 161: Russia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Russia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Russia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 170: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: Rest of Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 182: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 183: Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 197: Australia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Australia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Australia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 200: Australia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Australia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Australia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• INDIA
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 209: India Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: India Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: India 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 212: India Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: India Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: India 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 215: India Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 221: South Korea Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: South Korea Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: South Korea 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 224: South Korea Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: South Korea Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: South Korea 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 233: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 245: Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 246: Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 248: Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 260: Argentina Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Argentina Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Argentina 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 263: Argentina Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Argentina Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Argentina 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 272: Brazil Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Brazil Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Brazil 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 275: Brazil Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Brazil Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Brazil 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 284: Mexico Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Mexico Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: Mexico 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 287: Mexico Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Mexico Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Mexico 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 296: Rest of Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Rest of Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Rest of Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 308: Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 309: Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 310: Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 311: Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 313: Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 323: Iran Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Iran Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 325: Iran 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 326: Iran Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Iran Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 328: Iran 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 335: Israel Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Israel Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 337: Israel 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 338: Israel Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Israel Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 340: Israel 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 347: Saudi Arabia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Saudi Arabia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 349: Saudi Arabia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Saudi Arabia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 352: Saudi Arabia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 359: UAE Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 360: UAE Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 361: UAE 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 362: UAE Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 363: UAE Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 364: UAE 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 371: Rest of Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Rest of Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 373: Rest of Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 376: Rest of Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030
• AFRICA
  • Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 383: Africa Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Africa Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Downstream Processing Workflow and Upstream Processing Workflow Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 385: Africa 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Workflow Type - Percentage Breakdown of Value Sales for Downstream Processing Workflow and Upstream Processing Workflow for the Years 2015, 2025 & 2030
  • TABLE 386: Africa Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Africa Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 388: Africa 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use and Pharmaceutical & Biopharmaceutical Companies End-Use for the Years 2015, 2025 & 2030
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Adherent Culture and Suspension Culture Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Culture Type - Percentage Breakdown of Value Sales for Adherent Culture and Suspension Culture for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Adeno Associated Virus (AAV) Contract Development and Manufacturing Organizations by Application - Percentage Breakdown of Value Sales for Cell & Gene Therapy Development Application, Vaccine Development Application, Biopharmaceutical & Pharmaceutical Discovery Application and Biomedical Research Application for the Years 2015, 2025 & 2030

IV. COMPETITION